FDA Warning Letter to Medica Weight Loss Cites "Tirzepatide Is FDA-Approved" and "FDA-Approved Pharmacy" Claims
On June 8, 2026, FDA issued a warning letter to Medica Weight Loss after a March 2026 review of medicaweightloss.com, which offers compounded semaglutide and tirzepatide products. FDA says pictured labels identify "medica weight loss" as if it were the compounder "when in fact it is not," and cites claims including "Tirzepatide is FDA-approved…." and sourcing from an "FDA-approved pharmacy," noting compounded drugs are not FDA-approved and FDA does not approve pharmacies. FDA requested a written response within 15 business days.
What this meansFDA does not approve or license compounding pharmacies, so "FDA-approved pharmacy" language on a provider's site is worth questioning — how a provider describes its pharmacy partners says a lot about how carefully it operates.
Source: FDA original ↗